Moderna Shares Drop 10% After FDA Refusal on Flu Shot Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy MRNA?
Source: CNBC
- Moderna Stock Drop: Moderna's shares fell 10% after the FDA refused to review its application for the experimental flu shot mRNA-1010, prompting the company to request a meeting with the FDA to clarify the path forward, which could impact its vaccine development and market confidence.
- Humana's Earnings Miss: Despite beating profit and revenue expectations, Humana reported a fourth-quarter loss of $3.96 per share, better than the expected $4.01 loss, leading to a 6.7% drop in stock price, reflecting market concerns about its profitability.
- Generac's Resilience: Generac's stock rose nearly 6% despite missing fourth-quarter earnings expectations, as CEO Aaron Jagdfeld highlighted growth in the data center market, suggesting a potential increase in backlog from key suppliers to hyperscalers in the coming quarters.
- Mattel's Significant Decline: Mattel's adjusted earnings of 39 cents per share fell short of the expected 54 cents, resulting in a 28% drop in stock price, while its guidance for the year also disappointed, indicating serious challenges ahead for the toy manufacturer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
19 Analyst Rating
1 Buy
14 Hold
4 Sell
Hold
Current: 40.110
Low
17.00
Averages
29.36
High
63.00
Current: 40.110
Low
17.00
Averages
29.36
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MODERNA STOCK RISES 3.8% FOLLOWING STRONG Q4 REVENUE RESULTS
Earnings Performance: Moderna reported a 3.8% increase in shares following a revenue beat in the fourth quarter.
Market Reaction: The positive earnings report led to a favorable response from investors, boosting the company's stock price.
See More
Moderna Posts Smaller Loss Than Anticipated, But Stock Declines Following Earnings Report.
Moderna's Quarterly Results: Moderna reported better-than-expected quarterly results, indicating strong performance in its financials.
Stock Performance: Despite the positive earnings report, shares of Moderna slipped on Friday, reflecting market reactions.
See More
MODERNA EXECUTIVE EXPRESSES HOPE FOR EUROPEAN APPROVAL OF FLU-COVID COMBINATION VACCINE THIS YEAR - CONFERENCE CALL
- Moderna's Executive Statement: A Moderna executive expressed optimism regarding the approval of a flu-COVID combination vaccine in Europe this year.
- Focus on Vaccine Development: The statement highlights the company's ongoing efforts to innovate and expand its vaccine offerings in response to public health needs.
See More
U.S. Medical Groups Sue CDC to Block Vaccine Advisory Meeting
- Lawsuit Initiated: Several medical groups, including the American Academy of Pediatrics and the American Public Health Association, filed a lawsuit on Friday to prevent the CDC from holding its next vaccine advisory meeting, arguing that the CDC's overhaul of immunization guidelines could jeopardize public health.
- Vaccine Policy Changes: Under Secretary of Health and Human Services Robert F. Kennedy Jr., the CDC recommended earlier this year a significant reduction in the number of diseases covered by the childhood immunization schedule from 17 to 11, raising widespread concerns about the implications for public health.
- Committee Restructuring: Kennedy's abrupt dismissal of all 17 members of the CDC’s Advisory Committee on Immunization Practices in June, followed by the appointment of critics of mRNA vaccines, is viewed as a major interference in vaccine policy that could affect medical practices.
- Public Health Risks: Attorney James Oh stated that this policy change poses a “clear and present danger” to public health and could undermine the functions and missions of healthcare organizations, with Judge Murphy acknowledging the need for a timely decision in this case.
See More
US Stocks Close Mixed as Inflation Data Shapes Rate Expectations
- Inflation Data Impact: The Bureau of Labor Statistics reported a 0.2% month-over-month increase in the Consumer Price Index for January, with a 2.4% annual rise, which was below expectations and led to shifts in market expectations regarding Federal Reserve rate policies, with traders now betting on a potential 25 basis point cut in June, reflecting concerns over future economic slowdown.
- Tech Stocks Sell-Off: Amid fears of AI disruption, the Nasdaq Composite fell 0.2%, while the Dow Jones Industrial Average edged up 0.1%, but all three major indices posted weekly losses exceeding 1%, indicating a waning investor confidence in tech stocks.
- Divergent Stock Performances: Rivian (RIVN) shares surged over 25% following a strong fourth-quarter earnings report, while Pinterest (PINS) plummeted more than 20% due to revenue misses, highlighting varying market perceptions of companies' adaptability in the AI era.
- Increased Market Volatility: As investor concerns about the disruptive potential of AI intensified, stocks in wealth management, transportation, and logistics sectors faced significant declines, leading to a more cautious market sentiment that reflects uncertainty about future economic conditions.
See More
Health Care Stocks Rise as NYSE Index Gains 1.1%
- Strong Performance in Health Care: Health care stocks rose on Friday afternoon, with the NYSE Health Care Index gaining 1.1%, reflecting increased investor confidence in the sector, likely driven by an overall improvement in market sentiment.
- Market Sentiment Recovery: The rise in health care stocks may be correlated with a broader market recovery trend, as investors reassess the investment value of the health care sector after recent volatility, indicating optimism about future growth potential.
- Increased Investor Attention: With ongoing innovations and policy support in the health care industry, investor attention towards health care stocks has significantly increased, potentially attracting more capital into the sector and driving stock prices higher.
- Optimistic Industry Outlook: The growth potential and stability of the health care sector make it attractive amid economic uncertainties, leading investors to view it as a safe haven, further propelling the upward trend in health care stocks.
See More
MODERNA STOCK RISES 3.8% FOLLOWING STRONG Q4 REVENUE RESULTS
Earnings Performance: Moderna reported a 3.8% increase in shares following a revenue beat in the fourth quarter.
Market Reaction: The positive earnings report led to a favorable response from investors, boosting the company's stock price.
See More
Moderna Posts Smaller Loss Than Anticipated, But Stock Declines Following Earnings Report.
Moderna's Quarterly Results: Moderna reported better-than-expected quarterly results, indicating strong performance in its financials.
Stock Performance: Despite the positive earnings report, shares of Moderna slipped on Friday, reflecting market reactions.
See More
MODERNA EXECUTIVE EXPRESSES HOPE FOR EUROPEAN APPROVAL OF FLU-COVID COMBINATION VACCINE THIS YEAR - CONFERENCE CALL
- Moderna's Executive Statement: A Moderna executive expressed optimism regarding the approval of a flu-COVID combination vaccine in Europe this year.
- Focus on Vaccine Development: The statement highlights the company's ongoing efforts to innovate and expand its vaccine offerings in response to public health needs.
See More
U.S. Medical Groups Sue CDC to Block Vaccine Advisory Meeting
- Lawsuit Initiated: Several medical groups, including the American Academy of Pediatrics and the American Public Health Association, filed a lawsuit on Friday to prevent the CDC from holding its next vaccine advisory meeting, arguing that the CDC's overhaul of immunization guidelines could jeopardize public health.
- Vaccine Policy Changes: Under Secretary of Health and Human Services Robert F. Kennedy Jr., the CDC recommended earlier this year a significant reduction in the number of diseases covered by the childhood immunization schedule from 17 to 11, raising widespread concerns about the implications for public health.
- Committee Restructuring: Kennedy's abrupt dismissal of all 17 members of the CDC’s Advisory Committee on Immunization Practices in June, followed by the appointment of critics of mRNA vaccines, is viewed as a major interference in vaccine policy that could affect medical practices.
- Public Health Risks: Attorney James Oh stated that this policy change poses a “clear and present danger” to public health and could undermine the functions and missions of healthcare organizations, with Judge Murphy acknowledging the need for a timely decision in this case.
See More
US Stocks Close Mixed as Inflation Data Shapes Rate Expectations
- Inflation Data Impact: The Bureau of Labor Statistics reported a 0.2% month-over-month increase in the Consumer Price Index for January, with a 2.4% annual rise, which was below expectations and led to shifts in market expectations regarding Federal Reserve rate policies, with traders now betting on a potential 25 basis point cut in June, reflecting concerns over future economic slowdown.
- Tech Stocks Sell-Off: Amid fears of AI disruption, the Nasdaq Composite fell 0.2%, while the Dow Jones Industrial Average edged up 0.1%, but all three major indices posted weekly losses exceeding 1%, indicating a waning investor confidence in tech stocks.
- Divergent Stock Performances: Rivian (RIVN) shares surged over 25% following a strong fourth-quarter earnings report, while Pinterest (PINS) plummeted more than 20% due to revenue misses, highlighting varying market perceptions of companies' adaptability in the AI era.
- Increased Market Volatility: As investor concerns about the disruptive potential of AI intensified, stocks in wealth management, transportation, and logistics sectors faced significant declines, leading to a more cautious market sentiment that reflects uncertainty about future economic conditions.
See More
Health Care Stocks Rise as NYSE Index Gains 1.1%
- Strong Performance in Health Care: Health care stocks rose on Friday afternoon, with the NYSE Health Care Index gaining 1.1%, reflecting increased investor confidence in the sector, likely driven by an overall improvement in market sentiment.
- Market Sentiment Recovery: The rise in health care stocks may be correlated with a broader market recovery trend, as investors reassess the investment value of the health care sector after recent volatility, indicating optimism about future growth potential.
- Increased Investor Attention: With ongoing innovations and policy support in the health care industry, investor attention towards health care stocks has significantly increased, potentially attracting more capital into the sector and driving stock prices higher.
- Optimistic Industry Outlook: The growth potential and stability of the health care sector make it attractive amid economic uncertainties, leading investors to view it as a safe haven, further propelling the upward trend in health care stocks.
See More
